Arrayjet Secures Contract Worth $500k
Complete the form below to unlock access to ALL audio articles.
Arrayjet has secured an order for its Ultra Marathon Microarray Printer valued at $500,000 from Beijing-based life sciences company CapitalBio Technology. CapitalBio provides DNA clinical diagnostic kits and by using Arrayjet’s high throughput inkjet bio-printing instrument, the Midlothian medical instrumentation company will make a telling contribution to enhance CapitalBio’s production capacity for its range of biomedical diagnostic products.
This is a groundbreaking contract for Arrayjet as it continues its growing international reputation for its patented and proprietary inkjet bio-printing technology to further leading-edge life sciences research, diagnostics and an increasingly advanced health care system across the globe.
Arrayjet’s technology will be used to advance CapitalBio’s future research and manufacturing capabilities in, for example, DNA diagnostics and using microarray tools to assist further research into acquired infant deafness, thalassemia, and chromosomal abnormalities for pre-implantation genetic screening.
Detection kits designed for clinical diagnosis constitute an important part of CapitalBio Corporation’s products and services – the parent company operates four research institutes and five subsidiaries - and clinical diagnosis based on DNA detection is increasingly recognised and accepted by doctors and patients. As a result, the market for CapitalBio’s detection kits is expanding fast. To meet this demand, CapitalBio chose Arrayjet’s Ultra Marathon Microarray Printer to achieve this for its customer base involved in clinical diagnostics, scientific research, and bio-safety testing.
The Ultra Marathon gives CapitalBio the capacity to manufacture microarrays, often likened to microchips for biological tests, in a high-throughput and highly automated manner using some of the most advanced motion controls and linear encoders to enable the printing of DNA materials at high-density onto glass substrates. As part of its clinical diagnosis kits, the microarrays can provide answers to complex human health including inherited syndromes, the pre-symptomatic detection of cancer, autoimmune disease, and other treatable conditions.
Iain McWilliam, CEO of Arrayjet commented; “CapitalBio is one of the most respected names in the global life sciences field and this contract is hugely significant for us, helping to further our aims in the Far East. Moreover, the past year has seen keen interest in our range of Arrayjet instrumentation products from North America, Australia and now China, so I am delighted that our international focus continues to attract high quality biomedical and life science service providers.
This is a significant coup for a growing Scottish life science instrumentation company which now has dynamic international reach.” For CapitalBio, Dr. Junquan Xu, CEO of CapitalBio Technology comments; “I am impressed by the advanced technology and the innovative design of the Arrayjet Marathon microarray printer. We are glad to be the first user of the Arrayjet Ultra Marathon Microarray machine with the inline camera QC system. Arrayjet constantly develops its products. This makes us optimistic about the prospect of long-term partnership with them.”
Arrayjet has had strong financial support from Archangels, the prominent Scottish-based business angel syndicate. Archangel Director, Mike Rutterford comments: “This is yet another excellent contract achieved by Arrayjet and the ‘brand’ appears to becoming synonymous across the world with delivering instrumentation which has the precision and accuracy sought by many of the world’s top laboratories and science parks. Arrayjet is destined to be the partner of choice for so many of these research establishments.”